openPR Logo
Press release

Relapsing-Remitting Multiple Sclerosis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Immunic AG, Sanofi, Anokion, RemeGen, Biogen, Novartis, Celltrion, Imcyse SA, Takeda

11-23-2023 07:08 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Relapsing-Remitting Multiple Sclerosis Pipeline Analysis

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 25+ key pharma and biotech companies are working on 28+ pipeline drugs in the Relapsing-Remitting Multiple Sclerosis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Relapsing-Remitting Multiple Sclerosis Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Relapsing-Remitting Multiple Sclerosis Therapeutics Market.

The report provides a detailed description of the Relapsing-Remitting Multiple Sclerosis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Relapsing-Remitting Multiple Sclerosis Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/relapsing-remitting-multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Relapsing-Remitting Multiple Sclerosis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Relapsing-Remitting Multiple Sclerosis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Relapsing-Remitting Multiple Sclerosis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Relapsing-Remitting Multiple Sclerosis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Relapsing-Remitting Multiple Sclerosis treatment market.

Learn More about the Clinical and Commercial Development Activities in the Relapsing-Remitting Multiple Sclerosis Therapeutics Domain @
https://www.delveinsight.com/report-store/relapsing-remitting-multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Relapsing-Remitting Multiple Sclerosis Therapeutics Analysis
There are approx. 25+ key companies developing therapies for Relapsing-Remitting multiple sclerosis. Currently, Immunic is leading the therapeutics market with its Relapsing Remitting multiple sclerosis drug candidates in the most advanced stage of clinical development.

Relapsing-Remitting Multiple Sclerosis Companies in the Therapeutics Market Include:
• Immunic AG
• Sanofi
• Anokion
• RemeGen
• HuniLife Biotechnology
• Biogen
• Clene Nanomedicine
• Novartis
• Celltrion
• Imcyse SA
• Takeda
And Many Others

Emerging and Marketed Relapsing-Remitting Multiple Sclerosis Therapies Covered in the Report Include:
• IMU-838: Immunic AG
• Tolebrutinib: Sanofi
• Telitacicept: RemeGen
• ANK700: Anokion
And Many More

Get an in-depth Assessment of the Emerging Therapies and Relapsing-Remitting Multiple Sclerosis Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/relapsing-remitting-multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Relapsing-Remitting Multiple Sclerosis Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Relapsing Remitting multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type
Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Request for Sample PDF to Understand More About the Relapsing-Remitting Multiple Sclerosis Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/relapsing-remitting-multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Relapsing-Remitting Multiple Sclerosis Current Treatment Patterns
4. Relapsing-Remitting Multiple Sclerosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Relapsing-Remitting Multiple Sclerosis Late-Stage Products (Phase-III)
7. Relapsing-Remitting Multiple Sclerosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Relapsing-Remitting Multiple Sclerosis Discontinued Products
13. Relapsing-Remitting Multiple Sclerosis Product Profiles
14. Relapsing-Remitting Multiple Sclerosis Companies
15. Relapsing-Remitting Multiple Sclerosis Drugs
16. Dormant and Discontinued Products
17. Relapsing-Remitting Multiple Sclerosis Unmet Needs
18. Relapsing-Remitting Multiple Sclerosis Future Perspectives
19. Relapsing-Remitting Multiple Sclerosis Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/relapsing-remitting-multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

------------------------------------------------------------------------------------------------------------------------------
Discover DelveInsight's Comprehensive Market Research and Consulting Services:
https://www.delveinsight.com/market-research

Elevate your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics, at:
https://www.delveinsight.com/medical-devices

Empowering Cancer Care: DelveInsight's oncology consulting services offer personalized guidance and cutting-edge expertise to navigate the ongoing clinical, commercial, and regulatory developments, visit for more details:
https://www.delveinsight.com/oncology

Other Trending Healthcare Reports by DelveInsight
Functional Electrical Stimulation (FES) Devices Market
https://www.delveinsight.com/report-store/functional-electrical-stimulation-fes-devices-market

Hypoactive Sexual Desire Disorder Market
https://www.delveinsight.com/report-store/hypoactive-sexual-desire-disorder-hsdd-market

Complicated Intra-Abdominal Infections Market
https://www.delveinsight.com/report-store/complicated-intra-abdominal-infections-market

Malignant Pleural Mesothelioma (MPM) Market
https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-market

Mitochondrial Myopathies Market
https://www.delveinsight.com/report-store/mitochondrial-myopathies-market

Asthma Diagnostic Devices Market
https://www.delveinsight.com/report-store/asthma-diagnostic-devices-market

Mayus Kinase (jak) Inhibitors Market
https://www.delveinsight.com/report-store/mayus-kinase-inhibitors-market

Acute Heart Failure Market
https://www.delveinsight.com/report-store/acute-heart-failure-ahf-market

Bacterial Vaginosis Market
https://www.delveinsight.com/report-store/bacterial-vaginosis-market

Hyperphosphatemia Market
https://www.delveinsight.com/report-store/hyperphosphatemia-market

Pleural Effusion Market
https://www.delveinsight.com/report-store/pleural-effusion-market

Epidermolysis Bullosa Market
https://www.delveinsight.com/report-store/epidermolysis-bullosa-market

Gestational Diabetes Market
https://www.delveinsight.com/report-store/gestational-diabetes-market

Intratumoral Cancer Therapies Market
https://www.delveinsight.com/report-store/intratumoral-cancer-therapies-market

Wasting Syndrome Market
https://www.delveinsight.com/report-store/wasting-syndrome-market

Parkinson's Disease Related Dementia Market
https://www.delveinsight.com/report-store/parkinsons-disease-related-dementia-market

Vagus Nerve Stimulator (VNS) Global Market
https://www.delveinsight.com/report-store/vagus-nerve-stimulator-market

Abetalipoproteinemia Market
https://www.delveinsight.com/report-store/abetalipoproteinemia-market

Myelofibrosis (MF) Market
https://www.delveinsight.com/report-store/myelofibrosis-mf-market

Chemotherapy Induced Neutropenia (CIN) Market
https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market

Homozygous Familial Hypercholesterolemia Market
https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-market

Partial Onset seizures Market
https://www.delveinsight.com/report-store/partial-onset-seizures-market

West Nile Encephalitis Market
https://www.delveinsight.com/report-store/west-nile-encephalitis-market

Gonorrhea Market
https://www.delveinsight.com/report-store/gonorrhea-market

Polymyositis Market
https://www.delveinsight.com/report-store/polymyositis-market

Subarachnoid Hemorrhage Market
https://www.delveinsight.com/report-store/subarachnoid-hemorrhage-market

Acute Pancreatitis Market
https://www.delveinsight.com/report-store/acute-pancreatitis-market

Acute Respiratory Distress Syndrome (ARDS) Market
https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market

Hypercoagulability Market
https://www.delveinsight.com/report-store/hypercoagulability-market

PARP Inhibitors Market
https://www.delveinsight.com/report-store/parp-inhibitors-competitive-landscape-pipeline-and-market-analysis

Bacterial Conjunctivitis Market
https://www.delveinsight.com/report-store/bacterial-conjunctivitis-market

Desmoplastic Small Round Cell Tumors (DSRCTS) Market
https://www.delveinsight.com/report-store/desmoplastic-small-round-cell-tumors-market

Hemophilia with Inhibitor Market
https://www.delveinsight.com/report-store/hemophilia-with-inhibitor-market

Pelvic Inflammatory Disease Market
https://www.delveinsight.com/report-store/pelvic-inflammatory-disease-market

Hemorrhoids Market
https://www.delveinsight.com/report-store/hemorrhoids-market

PCSK9 Inhibitors Market
https://www.delveinsight.com/report-store/pcsk9-inhibitors-market

Stargardt Disease (STGD) Market
https://www.delveinsight.com/report-store/stargardt-disease-stgd-market

Dravet Syndrome Market
https://www.delveinsight.com/report-store/dravet-syndrome-market

Genital Warts Market
https://www.delveinsight.com/report-store/genital-warts-condyloma-acuminatum-market

Orthopedic Trauma Devices Market
https://www.delveinsight.com/report-store/orthopedic-trauma-devices-market

Acute Lymphoblastic Leukemia (ALL) Market
https://www.delveinsight.com/report-store/acute-lymphoblastic-leukemia-all-market

Erythema Market
https://www.delveinsight.com/report-store/erythema-market

Primary Open Angle Glaucoma (POAG) Market
https://www.delveinsight.com/report-store/primary-open-angle-glaucoma-poag-market

Cutaneous Lupus Erythematosus Market
https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-cle-market

Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Market
https://www.delveinsight.com/report-store/hospital-acquired-and-ventilator-associated-bacterial-pneumonia-market

Traumatic Brain Injury Assessment Devices Market
https://www.delveinsight.com/report-store/traumatic-brain-injury-assessment-management-devices-market

Cartilage Diseases Market
https://www.delveinsight.com/report-store/cartilage-diseases-market

Hormone Sensitive Advanced Prostate Cancer Market
https://www.delveinsight.com/report-store/hormone-sensitive-advanced-prostate-cancer-market

Neuromodulation Devices Global Market
https://www.delveinsight.com/report-store/neuromodulation-devices-market

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Relapsing-Remitting Multiple Sclerosis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Immunic AG, Sanofi, Anokion, RemeGen, Biogen, Novartis, Celltrion, Imcyse SA, Takeda here

News-ID: 3300767 • Views:

More Releases from DelveInsight Business Research LLP

Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical Stage Assets, Pharma Collaborations, Regulatory Developments, and the Global Market Growth Prospects
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Current Drug Trials, Potential Breakthrough Therapies, Pharma R&D Initiatives, and Future Market Transformations
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinical Advances, Pharma Strategies, and Market Evolution
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action, Ongoing Clinical Trials, Pharma Collaborations, and the Future Outlook of the Therapeutics Landscape
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights!

All 5 Releases


More Releases for Relapsing

Relapsing Refractory Multiple Myeloma Market is expected to reach USD 25 billion …
Relapsing refractory multiple myeloma (RRMM) is a severe form of blood cancer in which the disease recurs despite treatment or becomes resistant to therapy. As one of the most aggressive hematologic cancers, RRMM is characterized by the uncontrolled proliferation of plasma cells in the bone marrow, leading to bone damage, anemia, and kidney dysfunction. While treatments such as chemotherapy, proteasome inhibitors, and immunomodulatory drugs (IMiDs) have been used, RRMM remains
Relapsing Multiple Sclerosis Market Trends, Therapeutic Advances, and Growth Opp …
Relapsing Multiple Sclerosis (RMS) is a chronic, immune-mediated neurological condition characterized by episodes of acute neurological symptoms followed by periods of remission. Affecting millions globally, RMS imposes significant challenges on patients' quality of life, healthcare systems, and society at large. The Relapsing Multiple Sclerosis Market has gained substantial momentum as pharmaceutical companies, biotechnology firms, and healthcare providers focus on developing innovative disease-modifying therapies (DMTs) and personalized treatment strategies. With advancements
Relapsing Remitting Multiple Sclerosis Pipeline, Clinical Trials Assessment, and …
DelveInsight's, "Relapsing Remitting Multiple Sclerosis Pipeline Insight 2023" report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in the Relapsing-Remitting Multiple Sclerosis pipeline landscape. It covers the Relapsing Remitting Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Relapsing Remitting Multiple Sclerosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products
Global Relapsing-Remitting Multiple Sclerosis Market Research Report 2023-2029
Global Relapsing-Remitting Multiple Sclerosis Market: Driven factors and Restrictions factors The research report encompasses a comprehensive analysis of the factors that affect the growth of the market. It includes an evaluation of trends, restraints, and drivers that influence the market positively or negatively. The report also outlines the potential impact of different segments and applications on the market in the future. The information presented is based on historical milestones and current
Relapsing Refractory Multiple Myeloma Market Size in 7MM is expected to change f …
DelveInsight's "Relapsing Refractory Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Relapsing Refractory Multiple Myeloma, historical and forecasted epidemiology as well as the Relapsing Refractory Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Discover more about therapies set to grab major Relapsing Refractory Multiple Myeloma Market Share @ Relapsing Refractory Multiple Myeloma Market Size-
Relapsing-Remitting Multiple Sclerosis market: Drivers, Threats, and Opportuniti …
" The Relapsing-Remitting Multiple Sclerosis global market is thoroughly researched in this report, noting important aspects like market competition, global and regional growth, market segmentation and market structure. The report author analysts have estimated the size of the global market in terms of value and volume using the latest research tools and techniques. The report also includes estimates for market share, revenue, production, consumption, gross profit margin, CAGR, and other key